Abstract: The present invention relates to a composition which contains an intestinal bacterium belonging to Bacteroidetes and having an inflammation reducing activity, or a substance derived from the intestinal bacterium and having an inflammation reducing activity and which has at least one activity selected from an anti-inflammatory activity, an immunoregulation activity, an epithelial barrier restoring activity, an IL-10-inducing activity, and an IL-22-inducing activity, and to an ameliorating agent for an inflammatory disease, an autoimmune disease, or an infectious disease containing the intestinal bacterium and the substance derived from the intestinal bacterium and having an inflammation reducing activity.

Abstract: The present invention establishes a molecular therapy for glycogen storage disease type Ia. The present invention provides an oligonucleotide of 15-30 bases comprising a nucleotide sequence complementary to die cDNA of G6PC gene with c.648G>T mutation, wherein the oligonucleotide comprises a sequence complementary to a region comprising any site between the 82nd to the 92nd nucleotide from the 5? end of exon 5 of the G6PC gene with c.648C>T mutation, a pharmacologically acceptable salt or solvate thereof. Also provided is a pharmaceutical drug comprising the oligonucleotide, a pharmacologically acceptable salt or solvate thereof (e.g., therapeutic drug for glycogen storage disease type Ia).

Abstract: Provided is an oligonucleotide which may induce an editing activity of ADRC in cell and has excellent stability in a living body. The oligonucleotide includes a first oligonucleotide identifying a target RNA and a second oligonucleotide linked to the 5?-side of the first oligonucleotide. The first oligonucleotide consists of a target-corresponding nucleotide residue, an oligonucleotide of 10 to 24 residues at the 3?-side, and an oligonucleotide of 3 to 6 residues at the 5?-side. The second oligonucleotide has no nucleotide residue corresponding to a nucleotide residue of the target RNA or has a nucleotide residue which does not form a complementary pair at the 3?-end thereof and the number of residue is 3 to 6.

Abstract: Disclosed is an image display system including an eyeball state acquisition section that acquires information regarding a state of an eye of a user, a beam control section that adjusts, according to the information regarding the state of the eye, a beam state of image laser light for forming pixels of a display image, and an image projection section that projects the image laser light onto a retina of the user.

Abstract: Provided is an image projection system including an image projection unit that irradiates a physical object with image laser light for forming pixels of an image to be projected on the physical object, a reference light irradiation unit that irradiates the physical object with reference laser light emitted through an emission port common to the image laser light, and a shape measurement unit that detects, at a position circumscribing the emission port, the reference laser light reflected from the physical object and measures a three-dimensional shape of the physical object on the basis of a result of the detection.

Abstract: A sensor system includes a light source that applies, to an imaging target, light whose light amount gradually increases or gradually degreases, an event-driven type sensor that generates an event signal by detecting a fluctuation of reflection light from the imaging target after the application of the light whose light amount gradually increases or gradually degreases is started, and a gradation calculation unit that calculates a gradation of the imaging target on the basis of an elapsed period of time from the start of the application of the light whose light amount gradually increases or gradually decreases to the generation of the event signal.

Abstract: The present invention provides a vaccine for preventing and/or treating infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The present invention relates to a lipid particle encapsulating a nucleic acid molecule capable of expressing the S protein and/or a fragment thereof of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), wherein the lipid comprises a cationic lipid represented by general formula (Ia) or a pharmaceutically acceptable salt thereof: wherein R1 and R2 each independently represent a C1-C3 alkyl group; L1 represents a C17-C19 alkenyl group which may have one or a plurality of C2-C4 alkanoyloxy groups; L2 represents a C10-C19 alkyl group which may have one or a plurality of C2-C4 alkanoyloxy groups or a C10-C19 alkenyl group which may have one or a plurality of C2-C4 alkanoyloxy groups; and p is 3 or 4.

Abstract: A sensor system includes a sensor array and a gradation determination section. The sensor array includes a first sensor and a second sensor. The first sensor is configured to detect, with a first sensitivity, a variation in a quantity of light at a first pixel address. The second sensor is configured to detect, with a second sensitivity that is lower than the first sensitivity, a variation in a quantity of light at a second pixel address that is adjacent to or coincides with the first pixel address. The gradation determination section is configured to determine, when the first sensor generates a first event signal in response to a luminance variation event, a gradation of an object having caused the luminance variation event to occur, depending on whether or not the second sensor generates a second event signal in response to the luminance variation event.

Abstract: A sensor system includes a sensor array configured to include a first sensor and a second sensor, the first sensor detecting with a first sensitivity a variation in a quantity of light at a first pixel address, the second sensor detecting with a second sensitivity a variation in a quantity of light at a second pixel address, the second pixel address being adjacent to or coinciding with the first pixel address, the second sensitivity being lower than the first sensitivity, and an event signal processing section configured to output information indicative of a difference between times at which the first sensor and the second sensor each have generated an event signal in response to a luminance variation event.

Abstract: The present invention provides an immunity-inducing agent comprising a polynucleotide-peptide conjugate or a pharmaceutically acceptable salt thereof as an active component, wherein the polynucleotide-peptide conjugate consists of: a single-chain polynucleotide or polynucleotide derivative comprising a CpG motif; a peptide; and a spacer which is covalently bonded at one end thereof to the polynucleotide or polynucleotide derivative and covalently bonded at the other end thereof to the peptide, wherein the peptide is a peptide modified by substituting one or more contiguous amino acids at the N-terminus of an MHC-binding peptide with an amino acid having a reactive functional group which allows for the formation of a covalent bond with the spacer, wherein the one or more contiguous amino acids contain no anchor residues for MHC binding.

Abstract: An oligonucleotide that induces a site-specific editing for a target RNA, the oligonucleotide including a first oligonucleotide that specifies the target RNA, a second oligonucleotide that is linked to the 3?-side of the first oligonucleotide, a third oligonucleotide that is capable of forming a complementary pair together with the second oligonucleotide, and a first linking portion that links the second oligonucleotide and the third oligonucleotide. The first oligonucleotide is composed of a target-corresponding nucleotide residue that corresponds to an adenosine residue in the target RNA; an oligonucleotide of 10 to 30 residues linked to the 5?-side of the target-corresponding nucleotide residue and having a base sequence complementary to the target RNA; and an oligonucleotide of 3-6 residues linked to the 3?-side of the target-corresponding nucleotide residue and having a base sequence complementary to the target RNA.

Abstract: The present invention provides a vaccine for preventing and/or treating infections with human papillomavirus. The present invention relates to a lipid particle encapsulating a nucleic acid molecule capable of expressing the E6 and E7 antigens of human papillomavirus, wherein the lipid comprises a cationic lipid represented by general formula (Ia) or a pharmaceutically acceptable salt thereof: wherein R1 and R2 each independently represent a C1-C3 alkyl group; L1 represents a C17-C19 alkenyl group which may have one or a plurality of C2-C4 alkanoyloxy groups; L2 represents a C10-C19 alkyl group which may have one or a plurality of C2-C4 alkanoyloxy groups or a C10-C19 alkenyl group which may have one or a plurality of C2-C4 alkanoyloxy groups; and p is 3 or 4.

Abstract: The present invention provides a conjugate of an oligonucleotide having a nucleic acid sequence expected to have a pharmacological effect in hepatic parenchymal cells with a biantennary GalNAc unit, or a pharmaceutically acceptable salt thereof, and a medicament or the like containing the same as an active component.

Abstract: The present invention aims at establishing a novel therapy for facioscapulohumeral muscular dystrophy. An oligonucleotide or a pharmaceutically acceptable salt thereof, wherein the oligonucleotide comprises an oligonucleotide of 15-30 bases consisting of a nucleotide sequence complementary to the region of nucleotide Nos. 502-556 or 578-612 of DUX4-fl mRNA consisting of the nucleotide sequence as shown in SEQ ID NO: 1; the 5? and/or 3? end of the oligonucleotide may be chemically modified; and the oligonucleotide is capable of switching the splice form of the DUX4 gene from DUX4-fl to DUX4-s. A pharmaceutical drug comprising the above oligonucleotide or a pharmaceutically acceptable salt thereof (e.g. therapeutic for facioscapulohumeral muscular dystrophy).

Abstract: A sensor system includes a light source that applies, to an imaging target, light whose light amount gradually increases or gradually degreases, an event-driven type sensor that generates an event signal by detecting a fluctuation of reflection light from the imaging target after the application of the light whose light amount gradually increases or gradually degreases is started, and a gradation calculation unit that calculates a gradation of the imaging target on the basis of an elapsed period of time from the start of the application of the light whose light amount gradually increases or gradually decreases to the generation of the event signal.

Abstract: A sensor system includes a sensor array and a gradation determination section. The sensor array includes a first sensor and a second sensor. The first sensor is configured to detect, with a first sensitivity, a variation in a quantity of light at a first pixel address. The second sensor is configured to detect, with a second sensitivity that is lower than the first sensitivity, a variation in a quantity of light at a second pixel address that is adjacent to or coincides with the first pixel address. The gradation determination section is configured to determine, when the first sensor generates a first event signal in response to a luminance variation event, a gradation of an object having caused the luminance variation event to occur, depending on whether or not the second sensor generates a second event signal in response to the luminance variation event.

Abstract: An image processing apparatus includes a first reception section, a second reception section, an association processing section, an object detection section, and a process execution section. The first reception section receives image information acquired by an image sensor. The second reception section receives sound information that is acquired by one or plural directional microphones and that is generated for at least a partial region in a field of the image sensor. The association processing section associates the sound information with a pixel address of the image information indicating a position in the field. The object detection section detects, from the image information, at least a part of an object that is present in the field. The process execution section executes a predetermined process on the object on the basis of a result of the association performed by the association processing section.

Abstract: A sensor system includes a sensor array configured to include a first sensor and a second sensor, the first sensor detecting with a first sensitivity a variation in a quantity of light at a first pixel address, the second sensor detecting with a second sensitivity a variation in a quantity of light at a second pixel address, the second pixel address being adjacent to or coinciding with the first pixel address, the second sensitivity being lower than the first sensitivity, and an event signal processing section configured to output information indicative of a difference between times at which the first sensor and the second sensor each have generated an event signal in response to a luminance variation event.

Abstract: Provided is an information processing device including a light source control section that changes intensity of light of a light source which irradiates eyes of a user, a reception section that receives, from an event driven vision sensor including a sensor which generates an event signal when detecting a change in intensity of a light to be incident thereon, the event signal indicating a position and a time of the change in intensity of the light reflected by the eyes of the user, and a visual line detection section that identifies the light source corresponding to the event signal on the basis of a relative positional relation among the eyes of the user, the light source, and the vision sensor, and of the event signal generated at the same time that control is carried out by the light source control section, to detect a visual line of the user.

Abstract: To extend drive time in an imaging apparatus driven by a battery. The imaging apparatus includes a remaining battery level detection unit, a solid-state imaging element, and a control unit. In the imaging apparatus, the remaining battery level detection unit detects a remaining battery level of the battery. Furthermore, in the imaging apparatus, the solid-state imaging element captures image data. Moreover, in the imaging apparatus, the control unit controls the solid-state imaging element to capture image data so that the lower the remaining battery level measured by a remaining battery level measurement unit, the smaller the data amount of the image data to be captured in synchronization with a predetermined synchronization signal.